Abstract
Tardive dyskinesia (TD) has been recognised for nearly 50 years. It is associated with antipsychotic drugs and is usually persistent with no satisfactory treatment. It is believed to be under-documented in medical records. Many rating scales have been devised to measure TD. Studies have demonstrated variability between the rating scales on the measures of reliability and validity, the clinical setting used, the raters involved in the ratings and the provision of definitions and instructions. Scales that include too many items to be comprehensive become cumbersome and difficult to use. A compromise is to reduce the number of items and have add-in items for individual patients. A good example of this approach is the Abbreviated Dyskinesia Scale (ADS). Rating scales continue to be the best available methods to evaluate dyskinesia but in view of the shortcomings of validity, reliability and utility for clinical use, more efforts need to be done to improve current rating scales and to develop new ones.
Keywords: Tardive dyskinesia, rating scales, anti-psychotics, movement disorder, schizophrenia
Current Drug Targets
Title: A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia
Volume: 7 Issue: 9
Author(s): U. Taksh
Affiliation:
Keywords: Tardive dyskinesia, rating scales, anti-psychotics, movement disorder, schizophrenia
Abstract: Tardive dyskinesia (TD) has been recognised for nearly 50 years. It is associated with antipsychotic drugs and is usually persistent with no satisfactory treatment. It is believed to be under-documented in medical records. Many rating scales have been devised to measure TD. Studies have demonstrated variability between the rating scales on the measures of reliability and validity, the clinical setting used, the raters involved in the ratings and the provision of definitions and instructions. Scales that include too many items to be comprehensive become cumbersome and difficult to use. A compromise is to reduce the number of items and have add-in items for individual patients. A good example of this approach is the Abbreviated Dyskinesia Scale (ADS). Rating scales continue to be the best available methods to evaluate dyskinesia but in view of the shortcomings of validity, reliability and utility for clinical use, more efforts need to be done to improve current rating scales and to develop new ones.
Export Options
About this article
Cite this article as:
Taksh U., A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia, Current Drug Targets 2006; 7 (9) . https://dx.doi.org/10.2174/138945006778226589
DOI https://dx.doi.org/10.2174/138945006778226589 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microcirculation in Sepsis: New Perspectives
Current Vascular Pharmacology Molecular Targets of the Nitrogen Containing Bisphosphonates: The Molecular Pharmacology of Prenyl Synthase Inhibition
Current Pharmaceutical Design Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
Current Vascular Pharmacology Editorial from Editor-in-Chief: Are Implanted Upper Airway Stimulation Devices for the Treatment of Obstructive Sleep Apnea Ready for Primetime?
Current Respiratory Medicine Reviews Spatiotemporal Gait Characteristics Associated with Cognitive Impairment: A Multicenter Cross-Sectional Study, the Intercontinental “Gait, cOgnitiOn & Decline” Initiative
Current Alzheimer Research Developments and Applications of Moire Techniques for Deformation Measurement, Structure Characterization and Shape Analysis
Recent Patents on Materials Science The Developing Utility of Zebrafish Models for Cognitive Enhancers Research
Current Neuropharmacology PPAR-γ: Therapeutic Prospects in Parkinson's Disease
Current Drug Targets Abrupt Change on the Wettability of Vapor-Deposited Thin Silane Film Upon Evaporative Drying and Annealing
Current Nanoscience Live Impedance Measurements and Time-lapse Microscopy Observations of Cellular Adhesion, Proliferation and Migration after Ionizing Radiation
Current Pharmaceutical Biotechnology Differences Between Parkinson’s and Huntington’s Diseases and Their Role for Prioritization of Stem Cell-Based Treatments
Current Molecular Medicine Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Encephalopathy: A Vicious Cascade Following Forebrain Ischemia and Hypoxia
Central Nervous System Agents in Medicinal Chemistry Older Adults with Amnestic Mild Cognitive Impairment Exhibit Exacerbated Gait Slowing under Dual-Task Challenges
Current Alzheimer Research Editorial [Hot Topic: In Silico (Guest Editor: Alexandre G. de Brevern)]
Infectious Disorders - Drug Targets Recent Advances in the Characterization of Genetic Factors Involved in Human Susceptibility to Infection by Schistosomiasis
Current Genomics Ion Channel Defects in Idiopathic Epilepsies
Current Pharmaceutical Design Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Current Pharmaceutical Design Amyloid Under the Atomic Force Microscope
Protein & Peptide Letters Optogenetics of the Spinal Cord: Use of Channelrhodopsin Proteins for Interrogation of Spinal Cord Circuits
Current Protein & Peptide Science